{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T04:40:01Z","timestamp":1767156001819,"version":"build-2238731810"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T00:00:00Z","timestamp":1468281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T00:00:00Z","timestamp":1468281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hepatitis C Virus (HCV) is a major public health problem worldwide. While highly efficacious directly-acting antiviral agents have been developed in recent years, their high costs and relative inaccessibility make their use limited. Here, we describe new 1-(\u03c9-phenoxyalkyl)uracils bearing acetanilide fragment in 3 position of pyrimidine ring as potential antiviral drugs against HCV. Using a combination of various biochemical assays and\n                    <jats:italic>in vitro<\/jats:italic>\n                    virus infection and replication models, we show that our compounds are able to significantly reduce viral genomic replication, independently of virus genotype, with their IC\n                    <jats:sub>50<\/jats:sub>\n                    values in the nanomolar range. We also demonstrate that our compounds can block\n                    <jats:italic>de novo<\/jats:italic>\n                    RNA synthesis and that effect is dependent on a chemical structure of the compounds. A detailed structure-activity relationship revealed that the most active compounds were the N\n                    <jats:sup>3<\/jats:sup>\n                    -substituted uracil derivatives containing 6-(4-bromophenoxy)hexyl or 8-(4-bromophenoxy)octyl fragment at N\n                    <jats:sup>1<\/jats:sup>\n                    position.\n                  <\/jats:p>","DOI":"10.1038\/srep29487","type":"journal-article","created":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T02:55:16Z","timestamp":1468378516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Exploration of acetanilide derivatives of 1-(\u03c9-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication"],"prefix":"10.1038","volume":"6","author":[{"given":"Andrea","family":"Magri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander A.","family":"Ozerov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera L.","family":"Tunitskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir T.","family":"Valuev-Elliston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Wahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Pirisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander V.","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail S.","family":"Novikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,12]]},"reference":[{"key":"BFsrep29487_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jvh.12371","volume":"22","author":"H Wedemeyer","year":"2015","unstructured":"Wedemeyer, H., Dore, G. J. & Ward, J. W. Estimates on HCV disease burden worldwide-filling the gaps. J Viral Hepatitis 22 Suppl 1, 1\u20135 (2015).","journal-title":"J Viral Hepatitis"},{"key":"BFsrep29487_CR2","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1099\/vir.0.008300-0","volume":"90","author":"ME Burlone","year":"2009","unstructured":"Burlone, M. E. & Budkowska, A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol 90, 1055\u20131070 (2009).","journal-title":"J Gen Virol"},{"key":"BFsrep29487_CR3","unstructured":"Tan, S.-L. Hepatitis C viruses: genomes and molecular biology. (Horizon Scientific Press, 2006)."},{"key":"BFsrep29487_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2217\/fvl.13.127","volume":"9","author":"A Magri","year":"2014","unstructured":"Magri, A., Bocchetta, S., Burlone, M. E., Minisini, R. & Pirisi, M. Recent advances in HCV entry. Future Virology 9, 189\u2013205 (2014).","journal-title":"Future Virology"},{"key":"BFsrep29487_CR5","doi-asserted-by":"publisher","first-page":"10612","DOI":"10.1128\/JVI.01370-13","volume":"87","author":"D Paul","year":"2013","unstructured":"Paul, D., Hoppe, S., Saher, G., Krijnse-Locker, J. & Bartenschlager, R. Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. J Virol 87, 10612\u201310627 (2013).","journal-title":"J Virol"},{"key":"BFsrep29487_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.chom.2014.10.008","volume":"16","author":"D Paul","year":"2014","unstructured":"Paul, D., Madan, V. & Bartenschlager, R. Hepatitis C virus RNA replication and assembly: living on the fat of the land. Cell Host & Microbe 16, 569\u2013579 (2014).","journal-title":"Cell Host & Microbe"},{"key":"BFsrep29487_CR7","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/hep.24641","volume":"54","author":"MG Ghany","year":"2011","unstructured":"Ghany, M. G. et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54, 1433\u20131444 (2011).","journal-title":"Hepatology"},{"key":"BFsrep29487_CR8","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1016\/j.dld.2013.07.012","volume":"45","author":"R D\u2019Ambrosio","year":"2013","unstructured":"D\u2019Ambrosio, R. & Colombo, M. Safety of direct antiviral agents in real life. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 45 Suppl 5, S363\u2013S366 (2013).","journal-title":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver"},{"key":"BFsrep29487_CR9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.clinthera.2012.07.011","volume":"34","author":"SJ Matthews","year":"2012","unstructured":"Matthews, S. J. & Lancaster, J. W. Telaprevir: a hepatitis C NS3\/4A protease inhibitor. Clin Ther 34, 1857\u20131882 (2012).","journal-title":"Clin Ther"},{"key":"BFsrep29487_CR10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.coph.2012.06.005","volume":"12","author":"CM Wegzyn","year":"2012","unstructured":"Wegzyn, C. M. & Wyles, D. L. Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). Curr Opin Pharmacol 12, 556\u2013561 (2012).","journal-title":"Curr Opin Pharmacol"},{"key":"BFsrep29487_CR11","doi-asserted-by":"publisher","first-page":"i36","DOI":"10.1136\/gutjnl-2012-302144","volume":"61","author":"C Welsch","year":"2012","unstructured":"Welsch, C., Jesudian, A., Zeuzem, S. & Jacobson, I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61 Suppl 1, i36\u2013i46 (2012).","journal-title":"Gut"},{"key":"BFsrep29487_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cld.2012.09.007","volume":"17","author":"PJ Pockros","year":"2013","unstructured":"Pockros, P. J. Nucleoside\/nucleotide analogue polymerase inhibitors in development. Clinics in Liver Dis 17, 105\u2013110 (2013).","journal-title":"Clinics in Liver Dis"},{"key":"BFsrep29487_CR13","doi-asserted-by":"publisher","first-page":"g3308","DOI":"10.1136\/bmj.g3308","volume":"348","author":"ER Feeney","year":"2014","unstructured":"Feeney, E. R. & Chung, R. T. Antiviral treatment of hepatitis C. Bmj 348, g3308 (2014).","journal-title":"Bmj"},{"key":"BFsrep29487_CR14","unstructured":"U.S. Food and Drug Administration. FDA approves Viekira Pak to treat hepatitis C. FDA News Release (2014). Available at: http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm427530.htm."},{"key":"BFsrep29487_CR15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-015-0412-z","volume":"75","author":"ED Deeks","year":"2015","unstructured":"Deeks, E. D. Ombitasvir\/Paritaprevir\/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection. Drugs 75, 1027\u20131038 (2015).","journal-title":"Drugs"},{"key":"BFsrep29487_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/DHPS.S43304","volume":"6","author":"JN Gaetano","year":"2014","unstructured":"Gaetano, J. N. Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug, Healthcare and Patient Safety 6, 37\u201345 (2014).","journal-title":"Drug, Healthcare and Patient Safety"},{"key":"BFsrep29487_CR17","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/cid\/ciu012","volume":"58","author":"A Hill","year":"2014","unstructured":"Hill, A., Khoo, S., Fortunak, J., Simmons, B. & Ford, N. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 58, 928\u2013936 (2014).","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"key":"BFsrep29487_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","volume":"108","author":"E Poveda","year":"2014","unstructured":"Poveda, E. et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res 108, 181\u2013191 (2014).","journal-title":"Antiviral Res"},{"key":"BFsrep29487_CR19","doi-asserted-by":"publisher","first-page":"8940","DOI":"10.3748\/wjg.v19.i47.8940","volume":"19","author":"S Wu","year":"2013","unstructured":"Wu, S., Kanda, T., Nakamoto, S., Imazeki, F. & Yokosuka, O. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J Gastroenterol 19, 8940\u20138948 (2013).","journal-title":"World J Gastroenterol"},{"key":"BFsrep29487_CR20","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1016\/j.bmc.2013.05.009","volume":"21","author":"MS Novikov","year":"2013","unstructured":"Novikov, M. S. et al. Synthesis and anti-HCMV activity of 1-[\u03c9-(phenoxy)alkyl]uracil derivatives and analogues thereof. Bioorgan Med Chem 21, 4151\u20134157 (2013).","journal-title":"Bioorgan Med Chem"},{"key":"BFsrep29487_CR21","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.tetlet.2012.11.090","volume":"54","author":"MS Novikov","year":"2013","unstructured":"Novikov, M. S. et al. A highly facile approach to the synthesis of novel 2-(3-benzyl-2, 4-dioxo-1, 2, 3, 4-tetrahydropyrimidin-1-yl)-N-phenylacetamides. Tetrahedron Lett 54, 576\u2013578 (2013).","journal-title":"Tetrahedron Lett"},{"key":"BFsrep29487_CR22","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1021\/jm00168a029","volume":"33","author":"JB Jiang","year":"1990","unstructured":"Jiang, J. B. et al. Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization. J Med Chem 33, 1721\u20131728 (1990).","journal-title":"J Med Chem"},{"key":"BFsrep29487_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.antiviral.2009.04.007","volume":"83","author":"M Iro","year":"2009","unstructured":"Iro, M. et al. A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. Antiviral Res 83, 148\u2013155 (2009).","journal-title":"Antiviral Res"},{"key":"BFsrep29487_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1128\/JVI.05452-11","volume":"86","author":"AG Angus","year":"2012","unstructured":"Angus, A. G. et al. Conserved glycine 33 residue in flexible domain I of hepatitis C virus core protein is critical for virus infectivity. J Virol 86, 679\u2013690 (2012).","journal-title":"J Virol"},{"key":"BFsrep29487_CR25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1126\/science.285.5424.110","volume":"285","author":"V Lohmann","year":"1999","unstructured":"Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110\u2013113 (1999).","journal-title":"Science"},{"key":"BFsrep29487_CR26","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1128\/AAC.01256-12","volume":"56","author":"M Saeed","year":"2012","unstructured":"Saeed, M. et al. Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob Agents Chemother 56, 5365\u20135373 (2012).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep29487_CR27","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1128\/AAC.02932-15","volume":"60","author":"J Witteveldt","year":"2016","unstructured":"Witteveldt, J., Martin-Gans, M. & Simmonds, P. Enhancement of the Replication of Hepatitis C Virus Replicons of Genotypes 1 to 4 by Manipulation of CpG and UpA Dinucleotide Frequencies and Use of Cell Lines Expressing SECL14L2 for Antiviral Resistance Testing. Antimicrob Agents Chemother 60, 2981\u20132992 (2016).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep29487_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1099\/vir.0.006700-0","volume":"90","author":"J Witteveldt","year":"2009","unstructured":"Witteveldt, J. et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 90, 48\u201358 (2009).","journal-title":"J Gen Virol"},{"key":"BFsrep29487_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.stemcr.2014.04.018","volume":"3","author":"X Zhou","year":"2014","unstructured":"Zhou, X. et al. Modulating innate immunity improves hepatitis C virus infection and replication in stem cell-derived hepatocytes. Stem Cell Rep 3, 204\u2013214 (2014).","journal-title":"Stem Cell Rep"},{"key":"BFsrep29487_CR30","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1128\/JVI.02313-10","volume":"85","author":"R Li","year":"2011","unstructured":"Li, R. et al. Production of hepatitis C virus lacking the envelope-encoding genes for single-cycle infection by providing homologous envelope proteins or vesicular stomatitis virus glycoproteins in trans. J Virol 85, 2138\u20132147 (2011).","journal-title":"J Virol"},{"key":"BFsrep29487_CR31","doi-asserted-by":"publisher","first-page":"11979","DOI":"10.1074\/jbc.M210914200","volume":"278","author":"SS Carroll","year":"2003","unstructured":"Carroll, S. S. et al. Inhibition of hepatitis C virus RNA replication by 2\u2032-modified nucleoside analogs. J Biol Chem 278, 11979\u201311984 (2003).","journal-title":"J Biol Chem"},{"key":"BFsrep29487_CR32","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1128\/AAC.01534-07","volume":"52","author":"J Paeshuyse","year":"2008","unstructured":"Paeshuyse, J. et al. Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. Antimicrobial Agents Chemother 52, 3433\u20133437 (2008).","journal-title":"Antimicrobial Agents Chemother"},{"key":"BFsrep29487_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm1268","volume":"11","author":"T Wakita","year":"2005","unstructured":"Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med 11, 791\u2013796 (2005).","journal-title":"Nature Med"},{"key":"BFsrep29487_CR34","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1084\/jem.20021756","volume":"197","author":"B Bartosch","year":"2003","unstructured":"Bartosch, B., Dubuisson, J. & Cosset, F. L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197, 633\u2013642 (2003).","journal-title":"J Exp Med"},{"key":"BFsrep29487_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/978-1-59745-393-6_13","volume":"379","author":"AW Tarr","year":"2007","unstructured":"Tarr, A. W., Owsianka, A. M., Szwejk, A., Ball, J. K. & Patel, A. H. Cloning, expression, and functional analysis of patient-derived hepatitis C virus glycoproteins. Methods Mol Biol 379, 177\u2013197 (2007).","journal-title":"Methods Mol Biol"},{"key":"BFsrep29487_CR36","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1038\/nprot.2006.395","volume":"1","author":"T Kato","year":"2006","unstructured":"Kato, T. et al. Cell culture and infection system for hepatitis C virus. Nature Protocols 1, 2334\u20132339 (2006).","journal-title":"Nature Protocols"},{"key":"BFsrep29487_CR37","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1128\/JCM.43.11.5679-5684.2005","volume":"43","author":"T Kato","year":"2005","unstructured":"Kato, T. et al. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol 43, 5679\u20135684 (2005).","journal-title":"J Clin Microbiol"},{"key":"BFsrep29487_CR38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1053\/jhep.2002.31770","volume":"35","author":"M Frese","year":"2002","unstructured":"Frese, M. et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35, 694\u2013703 (2002).","journal-title":"Hepatology"},{"key":"BFsrep29487_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jcv.2004.03.009","volume":"31","author":"S Castelain","year":"2004","unstructured":"Castelain, S. et al. TaqMan amplification system with an internal positive control for HCV RNA quantitation. J Clin Virol 31, 227\u2013234 (2004).","journal-title":"J Clin Virol"},{"key":"BFsrep29487_CR40","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.1016\/j.bmcl.2011.07.018","volume":"21","author":"VL Tunitskaya","year":"2011","unstructured":"Tunitskaya, V. L. et al. Inhibition of the helicase activity of the HCV NS3 protein by symmetrical dimeric bis-benzimidazoles. Bioorgan Med Chem Lett 21, 5331\u20135335 (2011).","journal-title":"Bioorgan Med Chem Lett"},{"key":"BFsrep29487_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pep.2006.02.011","volume":"48","author":"AV Ivanov","year":"2006","unstructured":"Ivanov, A. V. et al. Development of the system ensuring a high-level expression of hepatitis C virus nonstructural NS5B and NS5A proteins. Protein Expression Purification 48, 14\u201323 (2006).","journal-title":"Protein Expression Purification"},{"key":"BFsrep29487_CR42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.febslet.2008.12.016","volume":"583","author":"AV Ivanov","year":"2009","unstructured":"Ivanov, A. V. et al. Hepatitis C virus NS5A protein modulates template selection by the RNA polymerase in in vitro system. FEBS Lett 583, 277\u2013280 (2009).","journal-title":"FEBS Lett"}],"updated-by":[{"DOI":"10.1038\/srep31529","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T00:00:00Z","timestamp":1472083200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep29487.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep29487","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep29487.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T01:00:30Z","timestamp":1672880430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep29487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,12]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,7,29]]}},"alternative-id":["BFsrep29487"],"URL":"https:\/\/doi.org\/10.1038\/srep29487","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,12]]},"assertion":[{"value":"14 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2016","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction has been published and is appended to both the HTML and PDF versions of this paper. The error not has been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29487"}}